Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01193361 · ClinicalTrials.gov registry record · Phase 2
Ph IIA Study (SOC +/- NS5B)
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT01193361 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 39 participants.
The verdict
NCT01193361, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
At least 1 dose of BMS-791325 can be identified which is safe, well tolerated, and efficacious when combined with peg-interferon alfa-2a (pegIFNα-2a)/ribavirin (RBV) for the treatment of treatment-naïve, chronically-infected hepatitis C virus (HCV) genotype 1 subjects
Interventions
- DRUG Placebo
- DRUG Ribavirin
- DRUG BMS-791325
- DRUG Peg-interferon alfa-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01193361
The ClinicalTrials.gov registry entry for NCT01193361 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01193361 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01193361 about?
NCT01193361 is a clinical study titled "Ph IIA Study (SOC +/- NS5B)". At least 1 dose of BMS-791325 can be identified which is safe, well tolerated, and efficacious when combined with peg-interferon alfa-2a (pegIFNα-2a)/ribavirin (RBV) for the treatment of treatment-naïve, chronically-infected hepatitis C virus (HCV) genotype 1 subjects
What is the current status of trial NCT01193361?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2010-10. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01193361?
The interventions under investigation include: Placebo (DRUG), Ribavirin (DRUG), BMS-791325 (DRUG), Peg-interferon alfa-2a (DRUG).
Who is sponsoring clinical trial NCT01193361?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.